Triumvira Immunologics is an immunotherapy company. Its T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC). The company focuses on the development of therapies for patients with solid or liquid malignancies and also with diseases other than cancer.